Dr. Christopher S. Snead MD

Recommended Articles

• Stem Cell Therapy Puts 4-year-old's Ultra Rare Lymphoma in Remission

  4-year-old Jovon Moss was diagnosed with X-linked Lymphoproliferative Syndrome, a rare disorder of the immune system that led him to being taken back and forth to the hospital since his 3rd birthday.Jovon’s journey began in September of last year, when his mother, Brittany Fluellen, first began to...

• New Diagnostic Tool Approved for Lymphoma

  A new diagnostic tool has been approved by the U.S. Food and Drug Administration (FDA) to help researchers identify leukemia and lymphoma cells by using a technique known as flow cytometry. A flow cytometry test for non-Hodgkin’s lymphoma (NHL) can help determine whether normal or abnormal DNA is...

• Little Boy Tugs at Heartstrings of Entire Community: Be the Match!

  Danny Feltwell, a young six-year-old boy, was diagnosed with T-cell lymphoblastic lymphoma when he was just two years old. After undergoing countless procedures and just four months from being considered fully cured, Danny relapsed and had to be re-hospitalized. The doctors found that a large tumor...

• Inspirational Blood Cancer Survivors

  Different forms of blood cancer are responsible for claiming the third most lives out of all the types of cancer. Additionally, there are currently no known preventative treatments for blood cancers, and the disease also impacts children and young people more than any other form of cancer.When it...

• The Lymphoma Research Foundation Announces Partnership with the Annals of Lymphoma

  The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization for lymphoma research, and they just announced their partnership with the Annals of Lymphoma (AOL). This was all revealed in September during Blood Cancer Awareness Month. LRF is devoted to exclusively funding...

• Treatment Update for Hodgkin Lymphoma

  Over time, research has uncovered ways of treating Hodgkin lymphoma (HL) to produce an 80% to 90% cure rate. For the remaining 10% to 20% who are either resistant to the primary treatment or have relapsed, their cancer can still be fatal.The standard care for those not yet cured has been a two-step...